Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 33,121 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

NCT03525444
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
53
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 30, 2026, 4:26 PM EDT
Not listed Not applicable Interventional

Investigation of Supplemental L-alanine in the Management of Dietary Fructose Intolerance

NCT04022434
View directory record Official record
Conditions
Fructose Intolerance
Interventions
Placedo, Alanine
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Results available

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

NCT03662334
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection
Drug · Device
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

Zinc for the Treatment of Herpes Simplex Labialis (HSL)

NCT00809809
View directory record Official record
Conditions
Herpes Simplex Labialis
Interventions
Zicam (Ionic zinc), placebo
Drug
Lead sponsor
Integrative Medicine Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Tempe, Arizona • Santa Fe, New Mexico • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Not applicable Interventional

The Effect of Amoxicillin Versus Placebo on Gastrointestinal Motility in Children

NCT01530009
View directory record Official record
Conditions
Functional Gastrointestinal Disorders
Interventions
Amoxicillin, Placebo
Drug · Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Results available

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03548987
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Anniston, Alabama • Fresno, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 3 Interventional

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

NCT05439616
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Anaheim, California • Imperial, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"

NCT03081416
View directory record Official record
Conditions
Headache, Intranasal Ketamine
Interventions
Ketamine, Normal saline, Metoclopramide, Ketorolac, Dexamethasone, Benadryl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 30, 2026, 4:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Drug Effects on Preference and Reward

NCT01722006
View directory record Official record
Conditions
Drug Addiction
Interventions
Pairing condition
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 30, 2026, 4:26 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

NCT01782352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo
Drug · Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 30, 2026, 4:26 PM EDT
Withdrawn Phase 1 Interventional

Pulmozyme for Sjogren's Associated Cough

NCT01357447
View directory record Official record
Conditions
Sjogren's Syndrome, Cough
Interventions
Dornase alfa, Saline
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

NCT06066528
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Phoenix, Arizona • Spring Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance

NCT01511107
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days
Drug
Lead sponsor
Alejandro Hoberman
Other
Eligibility
6 Months to 23 Months
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 30, 2026, 4:26 PM EDT
Recruiting Phase 2 Interventional

Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)

NCT07094711
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous
Interventions
Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine, preservative-free saline
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

NCT00364871
View directory record Official record
Conditions
Obesity
Interventions
naltrexone and bupropion SR
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 30, 2026, 4:26 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)

NCT07219771
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
PTP-01, Placebo control / saline vehicle
Biological · Other
Lead sponsor
Doron Therapeutics Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects

NCT05995444
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Results available

Promiseb Topical Cream for Cradle Cap

NCT01214434
View directory record Official record
Conditions
Cradle Cap, Infantile Seborrheic Dermatitis
Interventions
Promiseb Topical Cream, Bland emollient
Device · Other
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
30 Days and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Norwich, Connecticut • Louisville, Kentucky • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

NCT02404532
View directory record Official record
Conditions
Device Latency
Interventions
MIND1 System
Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

NCT01105598
View directory record Official record
Conditions
Mild Dyslipidemia
Interventions
ETC-1002 or placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

NCT01149421
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Phoenix, Arizona • Anaheim, California • Greenbrae, California + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 30, 2026, 4:26 PM EDT
Terminated Phase 3 Interventional Results available

Study of Tecovirimat for Human Mpox Virus

NCT05534984
View directory record Official record
Conditions
MPOX
Interventions
Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 30, 2026, 4:26 PM EDT
Completed Phase 2 Interventional

Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

NCT01293552
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ANT-1207, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Miami, Florida • West Palm Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Oct 30, 2026, 4:26 PM EDT